205 related articles for article (PubMed ID: 22334621)
41. Functional improvement and correlations with symptomatic improvement in adults with attention deficit hyperactivity disorder receiving long-acting methylphenidate.
Buitelaar JK; Casas M; Philipsen A; Kooij JJ; Ramos-Quiroga JA; Dejonckheere J; van Oene JC; Schäuble B
Psychol Med; 2012 Jan; 42(1):195-204. PubMed ID: 21733214
[TBL] [Abstract][Full Text] [Related]
42. When does it end? Attention-deficit/hyperactivity disorder in the middle aged and older populations.
Manor I; Rozen S; Zemishlani Z; Weizman A; Zalsman G
Clin Neuropharmacol; 2011; 34(4):148-54. PubMed ID: 21738027
[TBL] [Abstract][Full Text] [Related]
43. Efficacy and safety of dexmethylphenidate extended-release capsules in children with attention-deficit/hyperactivity disorder.
Greenhill LL; Muniz R; Ball RR; Levine A; Pestreich L; Jiang H
J Am Acad Child Adolesc Psychiatry; 2006 Jul; 45(7):817-23. PubMed ID: 16832318
[TBL] [Abstract][Full Text] [Related]
44. Atomoxetine treatment in adults with attention-deficit/hyperactivity disorder and comorbid social anxiety disorder.
Adler LA; Liebowitz M; Kronenberger W; Qiao M; Rubin R; Hollandbeck M; Deldar A; Schuh K; Durell T
Depress Anxiety; 2009; 26(3):212-21. PubMed ID: 19194995
[TBL] [Abstract][Full Text] [Related]
45. Parental perceived benefits of OROS-methylphenidate treatment for the child with attention-deficit/hyperactivity disorder and for parents themselves.
Kim JW; Park S; Kim BN; Shin MS; Cho SC; Kim JH; Son JW; Shin YM; Chung US; Han DH
Pharmacopsychiatry; 2013 Jun; 46(4):137-46. PubMed ID: 23364873
[TBL] [Abstract][Full Text] [Related]
46. Time course of treatment effect of OROS® methylphenidate in children with ADHD.
Armstrong RB; Damaraju CV; Ascher S; Schwarzman L; O'Neill J; Starr HL
J Atten Disord; 2012 Nov; 16(8):697-705. PubMed ID: 22084448
[TBL] [Abstract][Full Text] [Related]
47. An Open-label, Self-control, Prospective Study on Cognitive Function, Academic Performance, and Tolerability of Osmotic-release Oral System Methylphenidate in Children with Attention-deficit Hyperactivity Disorder.
Zheng Y; Liang JM; Gao HY; Yang ZW; Jia FJ; Liang YZ; Fang F; Li R; Xie SN; Zhuo JM
Chin Med J (Engl); 2015 Nov; 128(22):2988-97. PubMed ID: 26608976
[TBL] [Abstract][Full Text] [Related]
48. Effect of OROS methylphenidate on encopresis in children with attention-deficit/hyperactivity disorder.
Yılmaz S; Bilgiç A; Hergüner S
J Child Adolesc Psychopharmacol; 2014 Apr; 24(3):158-60. PubMed ID: 24168715
[TBL] [Abstract][Full Text] [Related]
49. Sustained release methylphenidate for the treatment of ADHD in amphetamine abusers: a pilot study.
Konstenius M; Jayaram-Lindström N; Beck O; Franck J
Drug Alcohol Depend; 2010 Apr; 108(1-2):130-3. PubMed ID: 20015599
[TBL] [Abstract][Full Text] [Related]
50. Emergence of tics in children with ADHD: impact of once-daily OROS methylphenidate therapy.
Palumbo D; Spencer T; Lynch J; Co-Chien H; Faraone SV
J Child Adolesc Psychopharmacol; 2004; 14(2):185-94. PubMed ID: 15319016
[TBL] [Abstract][Full Text] [Related]
51. A randomized, double-blind, placebo-controlled trial of augmentation with an extended release formulation of methylphenidate in outpatients with treatment-resistant depression.
Patkar AA; Masand PS; Pae CU; Peindl K; Hooper-Wood C; Mannelli P; Ciccone P
J Clin Psychopharmacol; 2006 Dec; 26(6):653-6. PubMed ID: 17110825
[TBL] [Abstract][Full Text] [Related]
52. A prospective open-label trial of long-acting liquid methylphenidate for the treatment of attention deficit/hyperactivity disorder in intellectually capable adults with autism spectrum disorder.
Joshi G; DiSalvo M; Wozniak J; Ceranoglu TA; Yule A; Surman C; Fried R; Galdo M; Hoskova B; Belser A; Biederman J
World J Biol Psychiatry; 2020 Apr; 21(4):274-290. PubMed ID: 31607204
[No Abstract] [Full Text] [Related]
53. Long-acting methylphenidate reduces collision rates of young adult drivers with attention-deficit/hyperactivity disorder.
Cox DJ; Davis M; Mikami AY; Singh H; Merkel RL; Burket R
J Clin Psychopharmacol; 2012 Apr; 32(2):225-30. PubMed ID: 22367664
[TBL] [Abstract][Full Text] [Related]
54. Long-term efficacy and safety outcomes with OROS-MPH in adults with ADHD.
Buitelaar JK; Trott GE; Hofecker M; Waechter S; Berwaerts J; Dejonkheere J; Schäuble B
Int J Neuropsychopharmacol; 2012 Feb; 15(1):1-13. PubMed ID: 21798108
[TBL] [Abstract][Full Text] [Related]
55. A randomized, placebo-controlled trial of three fixed dosages of prolonged-release OROS methylphenidate in adults with attention-deficit/hyperactivity disorder.
Medori R; Ramos-Quiroga JA; Casas M; Kooij JJ; Niemelä A; Trott GE; Lee E; Buitelaar JK
Biol Psychiatry; 2008 May; 63(10):981-9. PubMed ID: 18206857
[TBL] [Abstract][Full Text] [Related]
56. Genetic imaging study with [Tc-
Akay AP; Kaya GÇ; Kose S; Yazıcıoğlu ÇE; Erkuran HÖ; Güney SA; Oğuz K; Keskin D; Baykara B; Emiroğlu Nİ; Eren MŞ; Kızıldağ S; Ertay T; Özsoylu D; Miral S; Durak H; Gönül AS; Rohde LA
Prog Neuropsychopharmacol Biol Psychiatry; 2018 Aug; 86():294-300. PubMed ID: 29684537
[TBL] [Abstract][Full Text] [Related]
57. 12-month efficacy and safety of OROS MPH in children and adolescents with attention-deficit/hyperactivity disorder switched from MPH.
Hoare P; Remschmidt H; Medori R; Ettrich C; Rothenberger A; Santosh P; Schmit M; Spender Q; Tamhne R; Thompson M; Tinline C; Trott GE
Eur Child Adolesc Psychiatry; 2005 Sep; 14(6):305-9. PubMed ID: 16220214
[TBL] [Abstract][Full Text] [Related]
58. Once-daily OROS methylphenidate is safe and well tolerated in adolescents with attention-deficit/hyperactivity disorder.
McGough JJ; McBurnett K; Bukstein O; Wilens TE; Greenhill L; Lerner M; Stein M
J Child Adolesc Psychopharmacol; 2006 Jun; 16(3):351-6. PubMed ID: 16768642
[TBL] [Abstract][Full Text] [Related]
59. Effect of switching drug formulations from immediate-release to extended-release OROS methylphenidate : a chart review of Spanish adults with attention-deficit hyperactivity disorder.
Ramos-Quiroga JA; Bosch R; Castells X; Valero S; Nogueira M; Gómez N; Yelmo S; Ferrer M; Martínez Y; Casas M
CNS Drugs; 2008; 22(7):603-11. PubMed ID: 18547128
[TBL] [Abstract][Full Text] [Related]
60. Long-term Effects of Multimodal Treatment on Adult Attention-Deficit/Hyperactivity Disorder Symptoms: Follow-up Analysis of the COMPAS Trial.
Lam AP; Matthies S; Graf E; Colla M; Jacob C; Sobanski E; Alm B; Rösler M; Retz W; Retz-Junginger P; Kis B; Abdel-Hamid M; Müller HHO; Lücke C; Huss M; Jans T; Berger M; Tebartz van Elst L; Philipsen A;
JAMA Netw Open; 2019 May; 2(5):e194980. PubMed ID: 31150084
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
